Advertisement
Advertisement

More Related Content

Advertisement

More from ILRI(20)

Recently uploaded(20)

Advertisement

Gene editing in veterinary vaccine development: Status of the science

  1. Better lives through livestock Gene Editing in Veterinary Vaccine Development - status of the science Lucilla Steinaa Principal Scientist International Livestock Research Institute CGIAR Webinar series: “Genome Editing in Agriculture: Innovations for Sustainable Production and Food Systems” 6 October 2020
  2. 2 Veterinary Vaccine Types Attenuated vaccines Live Modified Live Inactivated vaccines Whole organisms Recombinant vaccines Subunit vaccines Chimeric vaccines Toxoid vaccines Detox of toxin
  3. 3 Genetically Modified Vaccine Types Vector-based. Inserted antigens for subunit vaccination • Viral: Poxvirus, adenoviruses and herpes virus • Bacterial: Salmonella, Listeria, Shigella (research) Modified Live attenuated vaccines (viruses, bacteria, protozoa) Using the modified organism as vaccine directly by deleting or slowing expression of virulence factors • Bacteria: Streptococcus, Escherichia, Salmonella • Virus: Rabies, ILTV, PRRS, BVD
  4. 4 Evolution of the GM Vaccine Types Modification of bacteria First recombinantly produced vaccine Viral / bacterial vectored vaccines Attenuated GM organisms Human Hepatitis B vaccine Canarypox vectored veterinary vaccines Poultry: Multivalent Modified Live attenuated Vaccines Salmonella vaccines Multi-pathogen vaccines
  5. 5Veterinary GM Vaccines (Vectored) – and Status Tawira et al. 2020
  6. 6 Gene Edited Vaccines (Vectored) on Market (Source: Company Homepages) Vaccine Company Molecular details Indication Development status Raboral V-RG Merial LAV. Oral Live vaccinia virus expressing Rabies antigen Rabies Innovax®-ND-IBD MSD Animal Health LAV. Recombinant Turkey Herpesvirus (Marek’s), with antigens from Newcastle Disease Virus and Infectious bursal disease Infectious Bursal Disease, Marek’s disease, Infectious bursal disease Marketed VAXXITEK® HVT+ IBD+ND Boeringer Ingelheim LAV. Recombinant Turkey Herpesvirus (Marek’s) with antigens from Newcastle Disese Virus and Infectious bursal disease virus Marek’s disease, Infectious bursal disease, Newcastle Disease Marketed VAXXITEK® HVT+IBD Boeringer Ingelheim LAV. Recombinant Turkey Herpesvirus (Marek’s) with antigens from Newcastle Disease Virus and Infectious bursal disease virus Marek’s disease, Infectious bursal disease. Marketed Suvaxyn®CSF Marker Zoites LAV. CP7_E2alfs. The main immunogen of CSF virus “Alfort/187”, glycoprotein E2, in a bovine viral diarrhea virus type 1 backbone Classical swine fever Marketed
  7. 7 Modified Live Vaccines on Market (European Medicines Agency) Vaccine Company Molecular details Indication Development status Hiprabovis IBR Marker Live Hipra Tk and gE deleted virus Infectious Bovine Rhinotracheitis Bovine Licensed Europe 2011 Equils StrepE Intervet Live streptococcus strain, aroA deletion Incapable of making folate Respiratory disease Horses Licensed Europe 2004 Poulvac Ecoli Salmonella Zoetis aroA deletion Incapable of making folate Colibacillosis Chicken, turkeys Salmonellosis Chicken Licensed Europe 2012 Bovela BVDV Boeringer Ingelheim Deletion of genes in type 1 and 2 Bovine Viral Diarrhea Cattle Licensed Europe 2014 Suvaxyn-PRRS- MLV Zoetis Modified Abortions, still birth due to PRRS virus Swine Licensed Europe 2017
  8. 8 Genetically Modified Vaccine Types Ramezanpour et al. Vaccine. 2016
  9. 9 GM Vaccines for Humans • The first: IMO-JEV, Japanese Encephalitis vaccine based on yellow fever vector. 2010 Japan. • The second: Dengvaxia, Japanese encephalitis vaccine, two genes from JEV inserted in yellow fever backbone. 2015, many countries, Europe, USA
  10. 10Gene Edited on More Complex Pathogens Vaccine Molecular details Indication Development status Referece Protozoa (Apicomplexan) Plasmodium falciparum (humans) Liver-stage antigens has been targeted Timed genome editing Gene editing for increased immunity Self destructive parasites Malaria Research M.C. Lee, et al. Microbiol Mol Biol Rev 2014 Protozoa Trypanosoma cruzi (humans) Deletion of genes for flagellum attachment (cruzei) Chagas disese Research Reviewed by Yoagubat et al. Trends in Parasitol 2020 Protozoa Trypanosoma brucei (humans) Sleeping sickness Research Reviewed by Yoagubat et al. Trends in Parasitol 2020 Protozoa Trypanosoma vivax (animals) Trypanosomiasis Research D ’Archivo et al. Plos Negl Trop Dis. 2011 Protozoa (Apicomplexan) Toxoplasma gondii (human and animals) Toxoplasmosis Research Shen et al. Methods Mol Biol. 2017 Protozoa (Apicomplexan) Crytosporidium spp (human and animals) Cryptosporidiosis Research Beverley. Nature 2015 Protozoa Babesia bovis (animals) Babesiosis Research Asada et al. Mol Biochem Parasitol 2012
  11. 11Gene Editing of Pathogens at ILRI for Vaccines and Research African Swine Fever (ASF) • Caused by a large DNA virus • Present in about 26 countries in Africa – constraint to the pig farming • Major problem in Eastern Europe, Russia and Asia. Contagious Bovine Pleuropneumonia (CBPP) • Caused by a Mycoplasma • One of the most serious cattle diseases in Africa. • Imposes an estimated minimal cost of > 100 M €/year in Africa and restricted trade. Technologies: CRISPR-Cas editing Synthetic biology Genome transplantation
  12. 12 CRISPR Modification of African Swine Fever Virus backbone: genotype IX isolate from outbreak in Kenya at the Ugandan border Onzere et al., Virus Genes. 2018 10 different viruses produced, ready for test in animals
  13. Modify fragments of ASFV Assemble genomes in yeast Reconstitute live virus Test infectivity and growth in tissue culture and in vivo Rapid Modification of ASFV to Obtain Vaccine Candidates Design Build Test Transform into yeast Isolate plasmid Propagate in coli Cut out and ligate loops loopsTransform YCpBac 1 2 3 1 2 3 1 2 3 wt wt wt F1R1 F2R2 F1R2 F1R1 F2R2 F1R2
  14. 14 Mmc – genome transplantation – model Schieck et al. Mol Microbiol 2016, Jores et al. JID 2018 GM12 YCPMmyc1.1 Δglf GM12 YCPMmyc1.1 Attenuation of Mycoplasma via Knock-out of Genes Involved in Polysaccharide Biosynthesis
  15. 15 What Is the Next? • Refinement of technologies - Inducible systems, self-destruction • DNA plasmid-coded attenuated viruses - Optimizing delivery • Bacterial vectors: Lots of ongoing clinical trials • Multivalent vaccines: Many pathogens in one • More complex pathogens: Helmiths
  16. 16 Mycoplasma work Elise Schieck (ILRI) Jorg Jores (ILRI) Carole Lartigue (CIRAD) Sanjay Vashee (JCVI) African swine fever work Hussein Abkallo (ILRI) Nicholas Svitek (ILRI) Elias Awino (ILRI) Bernard Odour (ILRI) Lucilla Steinaa (ILRI) Sanjay Vashee (JCVI) Walter Fuchs (FLI) Acknowledgements
  17. THANK YOU
Advertisement